Stereotactic body radiotherapy for localized prostate cancer: Pooled analysis from a multi-institutional consortium of prospective phase II trials
Christopher R. King,Debra Freeman,Irving D. Kaplan,Donald B. Fuller,Giampaolo Bolzicco,Sean P. Collins,Robert J. Meier,Jason Wang,Patrick A. Kupelian,Michael L. Steinberg,Alan W. Katz +10 more
Reads0
Chats0
TLDR
PSA relapse-free survival rates after SBRT compare favorably with other definitive treatments for low and intermediate risk patients, and the current evidence supports consideration of S BRT among the therapeutic options for these patients.About:
This article is published in Radiotherapy and Oncology.The article was published on 2013-11-01 and is currently open access. It has received 394 citations till now. The article focuses on the topics: PSA Failure & Androgen deprivation therapy.read more
Citations
More filters
Journal Article
CyberKnife for prostate cancer patients. Update of 200 patients treatment results
Leszek Miszczyk,A. Napieralska,Agnieszka Namysł-Kaletka,Grzegorz Woźniak,M. Stapor-Fudzinska,Grzegorz Głowacki,Andrzej Tukiendorf +6 more
TL;DR: CK based radioablation of LR and IR PCP is a safe and highly effective treatment modality and the lack of failures in the T2c group enables us to suggest that even more locally advanced patients with low PSA and maximal Gleason 3+4 could be treated with this modality.
Journal ArticleDOI
Patterns of stereotactic body radiation therapy: The influence of lung cancer treatment on prostate cancer treatment.
Bruce L. Jacobs,Jonathan G. Yabes,Samia H. Lopa,Dwight E. Heron,Chung-Chou H. Chang,Justin E. Bekelman,Joel B. Nelson,Julie P.W. Bynum,Amber E. Barnato,Jeremy M. Kahn +9 more
TL;DR: SBRT availability and experiential use for lung cancer influences its use for prostate cancer, but intensity of use for one does not relate to intensity ofuse for the other.
Journal ArticleDOI
Low Utilization of Androgen Deprivation Therapy Among Men Receiving Stereotactic Body Radiotherapy for Localized Prostate Cancer in the United States.
Trevor J. Royce,Jeffrey M. Switchenko,Chao Zhang,Daniel E. Spratt,Ronald C. Chen,Ashesh B. Jani,Sagar A. Patel +6 more
Book ChapterDOI
SAbR for Primary Prostate Cancer
TL;DR: This chapter will discuss the rationale, clinical experience, and techniques for optimal application of stereotactic ablative body radiosurgery (SAbR) in the management of localized prostate cancer.
Journal ArticleDOI
SMILE: Stereotaktische MRT-geführte Radiotherapie von lokal begrenzten Prostatakarzinomen
J. Ristau,Juliane Hörner-Rieber,C. Buchele,Sabine Klüter,C. Jäkel,Laurent Baumann,Nicolaus Andratschke,H. Garcia Schüler,Matthias Guckenberger,M. Li,Maximilian Niyazi,Stefanie Corradini,Claus Belka,Klaus Herfarth,J. Debus,S Körber +15 more
References
More filters
Journal ArticleDOI
Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer.
TL;DR: Significant late bladder and rectal toxicities from SBRT for prostate cancer are infrequent and the current evidence supports consideration of stereotactic body radiotherapy among the therapeutic options for localized prostate cancer.
Journal ArticleDOI
Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic experience.
TL;DR: The outcomes after high-dose hypofractionation were acceptable in the entire cohort of patients treated with the schedule of 70 at 2.5 Gy/fraction and the 5-year nadir + 2 ng/mL rate was 83% (95% confidence interval, 79–86%).
Journal ArticleDOI
Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: First clinical trial results
TL;DR: In this paper, the feasibility and toxicity of stereotactic hypofractionated accurate radiotherapy (SHARP) for localized prostate cancer were evaluated in a Phase I/II trial with 40 patients.
Journal ArticleDOI
Randomized trial comparing two fractionation schedules for patients with localized prostate cancer.
Himu Lukka,Charles Hayter,Jim A. Julian,Padraig Warde,W. James Morris,Mary Gospodarowicz,Mark Levine,Jinka Sathya,Richard Choo,Hugh M. Prichard,Michael Brundage,Winkle Kwan +11 more
TL;DR: This study was designed as a noninferiority investigation with a predefined tolerance of −7.5%.
Journal ArticleDOI
Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial
David P. Dearnaley,Isabel Syndikus,Georges Sumo,M. Bidmead,D. Bloomfield,Catharine H. Clark,Annie Gao,Shama Hassan,Alan Horwich,Robert Huddart,Vincent Khoo,Peter Kirkbride,Helen Mayles,P. Mayles,O. Naismith,Chris Parker,Helen Patterson,Martin J. Russell,Christopher D Scrase,C. South,John Staffurth,Emma Hall +21 more
TL;DR: A pre-planned preliminary safety analysis of side-effects in stages 1 and 2 of a randomised trial comparing standard and hypofractionated radiotherapy seems equally well tolerated as conventionally fractionated treatment at 2 years.
Related Papers (5)
Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial
David P. Dearnaley,Isabel Syndikus,Helen Mossop,Vincent Khoo,Alison Birtle,D. Bloomfield,John Graham,Peter Kirkbride,John P Logue,Zafar Malik,Julian Money-Kyrle,Joe M. O'Sullivan,Miguel Panades,Chris Parker,Helen Patterson,Christopher D Scrase,John Staffurth,Andrew Stockdale,Jean Tremlett,M. Bidmead,Helen Mayles,O. Naismith,C. South,Annie Gao,Clare Cruickshank,Shama Hassan,Julia Pugh,Clare Griffin,Emma Hall +28 more
Fractionation and protraction for radiotherapy of prostate carcinoma
David J. Brenner,Eric J. Hall +1 more